非麦角类 D2 多巴胺激动剂 CV 205 - 502 可降低肢端肥大症患者的生长激素浓度。

The non ergot D2-dopamine agonist CV 205-502 decreases growth hormone concentrations in acromegalic patients.

作者信息

Svoboda T, Kotzmann H, Clodi M, Bernecker P, Geyer G, Luger A

机构信息

Department of Medicine III, University of Vienna, Austria.

出版信息

Endocr Res. 1994 Feb;20(1):59-63. doi: 10.1080/07435809409035856.

DOI:10.1080/07435809409035856

PMID:7909510

Abstract

It was the aim of this study to test for a possible effect of the new non ergot dopamine agonist CV 205-502 on plasma growth hormone (GH) concentrations in acromegaly. 10 acromegalic patients received a single oral dose of 150 micrograms CV 205-502 after an overnight fast. As a control group 7 acromegalic patients undertook the same procedure without receiving any drug. Blood samples were drawn hourly up to 7 hours thereafter for determination of GH. Plasma growth hormone concentrations decreased by 48.8 +/- 8.7%. The nadir was observed 3 hours after CV 205-502 was administered and GH concentrations remained suppressed throughout the 7 hours of the test period. In contrast GH plasma concentrations in the control group remained stable. We conclude that acute administration of CV 205-502 suppresses GH secretion in acromegalic patients and thus could serve as an alternative therapy in acromegaly.

摘要

本研究旨在测试新型非麦角多巴胺激动剂CV 205-502对肢端肥大症患者血浆生长激素（GH）浓度的可能影响。10例肢端肥大症患者在禁食过夜后口服150微克CV 205-502单剂量。作为对照组，7例肢端肥大症患者进行相同操作但未接受任何药物。此后每小时采集血样直至7小时，以测定GH。血浆生长激素浓度下降了48.8±8.7%。在给予CV 205-502后3小时观察到最低点，并且在测试期的7小时内GH浓度一直受到抑制。相比之下，对照组的GH血浆浓度保持稳定。我们得出结论，急性给予CV 205-502可抑制肢端肥大症患者的GH分泌，因此可作为肢端肥大症的替代疗法。